Results 1 to 10 of about 9,558 (157)
An international comparative analysis and roadmap to sustainable biosimilar markets
Frontiers in Pharmacology, 2023 Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability of biosimilar markets.
Khalid A Alnaqbi +2 more
exaly +3 more sources
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
Biomedicines, 2022 This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.
Martina Burlando +2 more
exaly +3 more sources
Frontiers in Pharmacology, 2023 Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosimilar
Elif Car +2 more
exaly +3 more sources
Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies
Drug Metabolism and Pharmacokinetics, 2019 The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Akiko Ishii-Watabe
exaly +3 more sources
ESMO Open, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+9 more sources
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy
mAbs, 2022 The α-Gal epitope consisting of the terminal trisaccharide Galα1,3Galβ1,4GlcNAc exposed on cell or protein surfaces can cause severe immune reactions, such as hypersensitivity reactions, in humans.
Arthur Hinterholzer +6 more
doaj +1 more source
PLoS ONE, 2022 Healthcare systems have reached a critical point regarding the question of whether biosimilar substitution should become common practice. To move the discussion forward, the study objective was to investigate the views of experts from medicines agencies ...
Louise C. Druedahl +6 more
doaj +2 more sources
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Pharmaceuticals, 2021 Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals.
Félix Lobo, Isabel Río-Álvarez
doaj +1 more source
Knowledge and Perception of Iraqi Pharmacists Towards Biosimilar Medicines
Iraqi Journal of Pharmaceutical Sciences, 2021 Biosimilars are non-innovative copy versions of biologic medicines which are proven to be clinically equivalent to, as effective and as safe as their reference biologics.
Ashwaq J. Mohammed, Dheyaa J. Kadhim
doaj +1 more source
Scientific Reports, 2022 TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment.
Hugo Jourdain +3 more
doaj +1 more source